Are you in need of treatment for your chronic inflammatory demyelinating polyneuropathy (CIPD)?

Are you in need of treatment for your chronic inflammatory demyelinating polyneuropathy (CIPD)?

Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Wrist pain, hand

The Study

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, chronic autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensation
  • The disease can be disabling, though the degree of disability varies; more than half of patients cannot walk unaided when symptoms are at their worst
  • Both cellular and humoral components of the immune system have been implicated and evidence suggests that a number of autoantibodies identified in CIDP patients are pathogenic

Study Benefits:

  • Compensation for time and travel
  • Free medication and study related care
  • May benefit your CIDP symptoms
  •  

Study Participant Criteria :

  • 18 years of age or older
  • Diagnosed with active CIDP
  • Male or female

Study Participant Expectations :

  • 11-week treatment period
  • 8 visits to the research clinic and 6 interim phone calls

“Did You Know”

  • Epidemiological studies estimate that the prevalence of CIDP ranges from 0.67-10.3 cases per 100,000 people
  • CIDP predominantly affects males, and typically occurs in middle to old age; the incidence increases with age, rising to 1.5 times the overall average in people over 65 years of age

Register for a Study